Skip to main content

Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc

In Order to Read Online or Download Overcoming Resistance To Egfr Inhibitors In Egfr Mutant Nsclc Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Current Applications for Overcoming Resistance to Targeted Therapies

Current Applications for Overcoming Resistance to Targeted Therapies Book
Author : Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi
Publisher : Springer
Release : 2019-07-15
ISBN : 303021477X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

Lung Cancer and Personalized Medicine Novel Therapies and Clinical Management

Lung Cancer and Personalized Medicine  Novel Therapies and Clinical Management Book
Author : Aamir Ahmad,Shirish M. Gadgeel
Publisher : Springer
Release : 2015-12-24
ISBN : 3319249320
Language : En, Es, Fr & De

GET BOOK

Book Description :

This, the second of two volumes on personalized medicine in lung cancer, touches upon the recent progress in targeted drug development based on genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy of lung cancer patients. With chapters on state-of-the-art therapies and technologies written by leading experts working to develop novel companion diagnosis tools for the personalized treatment of lung cancer patients, this volume brings readers up-to-date by presenting the current knowledge on the efforts to make personalized management of lung cancer patients a reality.

AACR 2016 Abstracts 1 2696

AACR 2016  Abstracts 1 2696 Book
Author : American Association for Cancer Research (AACR)
Publisher : CTI Meeting Technology
Release : 2016-03-28
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

The AACR Annual Meeting is a must-attend event for cancer researchers and the broader cancer community. This year's theme, "Delivering Cures Through Cancer Science," reinforces the inextricable link between research and advances in patient care. The theme will be evident throughout the meeting as the latest, most exciting discoveries are presented in every area of cancer research. There will be a number of presentations that include exciting new data from cutting-edge clinical trials as well as companion presentations that spotlight the science behind the trials and implications for delivering improved care to patients. This book contains abstracts 1-2696 presented on April 17-18, 2016, at the AACR Annual Meeting.

Third Generation EGFR Inhibitors

Third Generation EGFR Inhibitors Book
Author : Harun M. Patel,Rahul Pawara,Sanjay J. Surana
Publisher : Elsevier
Release : 2018-11-27
ISBN : 0081026625
Language : En, Es, Fr & De

GET BOOK

Book Description :

Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends. This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics. Includes full synthetic schemes of all approved and in-trial third generation inhibitors Highlights the emergence of fourth generation EGFR inhibitors and the possibilities of them overcoming constraints of third generation compounds Provides a structural correlation of third and fourth generation EGFR inhibitors, reviewing both their design strategies and typical anticancer activity

Second Line Treatment of Non Small Cell Lung Cancer Clinical Pathological and Molecular Aspects of Novel Promising Drugs

Second Line Treatment of Non Small Cell Lung Cancer  Clinical  Pathological and Molecular Aspects of Novel Promising Drugs Book
Author : Umberto Malapelle,Pierlorenzo Pallante
Publisher : Frontiers Media SA
Release : 2017-08-29
ISBN : 2889452638
Language : En, Es, Fr & De

GET BOOK

Book Description :

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and in the population receiving the maintenance therapy over 16 months. Given these results, more than 60% of patients may receive a second line therapy with further opportunities to improve the length and quality of life. For patients not harbouring targetable DNA mutations newer options will be available for second line therapeutic schemes and two major assets seem to be promising: immune modulation and anti-angiogenetic agents. In particular, anti PD1/PDL1 antibodies, VEGFR antibodies and TKIs, these latter combined with standard chemotherapy docetaxel advance the median overall survival of 12 months. These drugs have a different mechanism of action, various adverse events and their activity is different depending on the types of population. However, the biomarkers’ activity and efficacy prediction are not fully or totally understood. In addition, also for patients with DNA targetable mutations new drugs seems to be promising for the use in the second line therapeutic protocols. In particular, drugs selectively directed against ALK translocation and mutational events and EGFR T790M secondary mutations seems to be very promising. In this Research Topic we critically discuss the older therapies and the historical development of second line, putting in to perspective the new agents available in clinical practice. We discuss their importance from a clinical point of view, but also consider and exploit the complex molecular mechanisms responsible of their efficacy or of the subsequently observed resistance phenomena. In this perspective, the undercovering and characterization of novel predictive biomarkers by NGS technology, the characterization of novel actors in the signal transduction pathway modulating the response of the cells, the optimization of new diagnostic tool as the evaluation of liquid biopsy and the implementation of more suitable pre-clinical models are crucial aspects dissected too. Nivolumab, nintedanib and ramucirumab probably will give the opportunity to improve the efficacy outcomes for the treatment of wild type tumours in second line therapeutic schemes, but many aspects should be debated in order that these agents are made available to patients, planning ahead a therapeutic strategy, beginning from the first line therapy, to the subsequent ones in a logical and affordable manner. As well, for treatment of mutated tumours, mutated EGFR irreversible inhibitors such as rociletinib and AZD9291, and ALK targeting drugs ceritinib and alectinib will also play an important role in the immediate future. Probably the right way is to give all the available opportunities to patients, but challenges and pitfalls should be carefully debated, and by launching this Research Topic we tried to give some practical insights in this changing landscape.

Molecular Oncology An Issue of Surgical Pathology Clinics E Book

Molecular Oncology  An Issue of Surgical Pathology Clinics   E Book Book
Author : Jennifer Hunt
Publisher : Elsevier Health Sciences
Release : 2012-11-12
ISBN : 1455750530
Language : En, Es, Fr & De

GET BOOK

Book Description :

Clinically accessible information for pathologists on the fast moving field of molecular pathology and oncology, addressing molecular and genetic approaches to the diagnosis and classification of tumors, predictive biomarkers for treatment response and disease progression. Recurrent in this series, summaries are provided of Key Features of tumor, Key molecular prognostic markers and therapeutic markers, Tumor suppressor genes, and Oncogenes. Topics include molecular pathology of: Breast, Gastrointestinal, Head and Neck, Genitourinary, Gynecologic, Hematopathology, Lung, Neuropathology, Pancreas/Biliary, and Sarcome.

Guide to Targeted Therapies Treatment Resistance in Lung Cancer

Guide to Targeted Therapies  Treatment Resistance in Lung Cancer Book
Author : Federico Cappuzzo
Publisher : Springer
Release : 2015-10-15
ISBN : 3319207415
Language : En, Es, Fr & De

GET BOOK

Book Description :

This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide.

EGFR Inhibitors Advances in Research and Application 2013 Edition

EGFR Inhibitors   Advances in Research and Application  2013 Edition Book
Author : N.A
Publisher : ScholarlyEditions
Release : 2013-06-21
ISBN : 1481675176
Language : En, Es, Fr & De

GET BOOK

Book Description :

EGFR Inhibitors—Advances in Research and Application: 2013 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about Lapatinib in a concise format. The editors have built EGFR Inhibitors—Advances in Research and Application: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Lapatinib in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of EGFR Inhibitors—Advances in Research and Application: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Targeted Therapies in Lung Cancer Management Strategies for Nurses and Practitioners

Targeted Therapies in Lung Cancer  Management Strategies for Nurses and Practitioners Book
Author : Marianne Davies,Beth Eaby-Sandy
Publisher : Springer
Release : 2019-07-16
ISBN : 3030165507
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.

Rational Design of Selective Irreversible Kinase Inhibitors A Structural Bioinformatics Approach

Rational Design of Selective  Irreversible Kinase Inhibitors  A Structural Bioinformatics Approach Book
Author : Michael Steven Cohen
Publisher :
Release : 2006
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

The human genome encodes approximately 500 protein kinases, which are involved in myriad cellular processes essential for homeostasis. Small molecule inhibitors that potently and selectively block the activity of kinases are not only useful as tools to precisely dissect the cellular role of their molecular targets, but also have therapeutic value.

Successes and Limitations of Targeted Cancer Therapy

Successes and Limitations of Targeted Cancer Therapy Book
Author : S. Peters,R.A. Stahel
Publisher : Karger Medical and Scientific Publishers
Release : 2014-02-19
ISBN : 3318025429
Language : En, Es, Fr & De

GET BOOK

Book Description :

The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies.

Clinical Genomics Practical Applications for Adult Patient Care

Clinical Genomics  Practical Applications for Adult Patient Care Book
Author : Michael T. Murray, MD,Mark Babyatski, MD
Publisher : McGraw Hill Professional
Release : 2013-11-07
ISBN : 0071622446
Language : En, Es, Fr & De

GET BOOK

Book Description :

The first book on the clinical application of genetics in primary care medicine, Clinical Genomics focuses on the everyday application of genetic assessment and its diagnostic, therapeutic, and preventive implications in clinical practice. Unlike traditional textbooks on medical genetics and dysmorphology, this is a clinical reference that covers many of the common diseases seen in everyday medical practice. Features: endorsed by the American College of Physicians; addresses the genetic basis of common chronic diseases, not just the classic diseases of dysmorphology.

Handbook of Cell Signaling

Handbook of Cell Signaling Book
Author : Ralph A. Bradshaw,Edward A. Dennis
Publisher : Academic Press
Release : 2010
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

KEY FEATURES: * Contains over 350 chapters of comprehensive coverage on cell signaling * Includes discussion on topics from ligand/receptor interactions to organ/organism responses * Provides user-friendly, well-illustrated, reputable content by experts in the field DESCRIPTION: Handbook of Cell Signaling, Three-Volume Set, 2e, is a comprehensive work covering all aspects of intracellular signal processing, including extra/intracellular membrane receptors, signal transduction, gene expression/translation, and cellular/organotypic signal responses. The second edition is an up-to-date, expanded reference with each section edited by a recognized expert in the field. Tabular and well illustrated, the Handbook will serve as an in-depth reference for this complex and evolving field. Handbook of Cell Signaling, 2/e will appeal to a broad, cross-disciplinary audience interested in the structure, biochemistry, molecular biology and pathology of cellular effectors.

Oncology

Oncology Book
Author : N.A
Publisher :
Release : 2008
ISBN :
Language : En, Es, Fr & De

GET BOOK

Book Description :

Lung Cancer

Lung Cancer Book
Author : N.A
Publisher : Demos Medical Publishing
Release : 2012-05-18
ISBN : 1617050970
Language : En, Es, Fr & De

GET BOOK

Book Description :

With contributions from internationally recognized experts, Lung Cancer details the current management of lung cancer and reviews new therapies in development for lung cancer, with an emphasis on therapeutic exploitation of the heterogeneous nature of lung tumors at the molecular level. Coverage includes discussion of multiple new agents that have been shown to impact overall survival as well as articles covering molecular biology of lung cancer, chemotherapy regimens for lung cancer, the emergence of maintenance therapy, the complexity of radiotherapy in the chest, the impact of adjuvant chemotherapy for resected non-small cell lung cancer, surgical considerations for early-stage lung cancer, and more. This book is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows. Emerging Cancer Therapeutics features: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice

The MD Anderson Manual of Medical Oncology Second Edition

The MD Anderson Manual of Medical Oncology  Second Edition Book
Author : Hagop M. Kantarjian,Robert A. Wolff
Publisher : McGraw Hill Professional
Release : 2011-04-22
ISBN : 0071701052
Language : En, Es, Fr & De

GET BOOK

Book Description :

State-of-the-art approaches to cancer management from the world's #1 oncology center The perfect clinical desk manual from the experts at MD Anderson Cancer Center Read the outstanding reviews of the previous edition: "As a detailed guide, [the book] offers practitioners a clear, user-friendly approach to the care of patients with cancer." -- New England Journal of Medicine "The portions of the text that summarize the chemotherapeutic literature are helpful and potentially useful to a busy medical oncologist. The graphic representations and flow charts are of high quality, are well designed and easy to follow, and are clinically useful. A number of good photographs have been provided that illustrate pathologic conditions....the Manual is well written, has extremely useful graphics, and represents a useful entry point for those interested in the management of malignant diseases." -- International Journal of Radiation Oncology, Biology, Physics "...[MD Anderson Manual of Medical Oncology] fulfills its goals of helping clinicians quickly evaluate therapeutic regimens and possibilities. Surgeons and radiation oncologists will find the text useful as a reference guide to what the medical oncologist can do and how the medical oncologist views their disciplines. The text is also of considerable help for physicians studying for board certification or recertification in medical oncology. Practicing medical oncologists would do well to have it in their personal libraries." -- Journal of the American Medical Association MD Anderson Manual of Medical Oncology offers clinicians an authoritative, easy-to-follow guide to the medical management of patients with cancer and its complications. Featuring concise but practical text and a large number of decision-making algorithms, the book gives physicians a current, templated approach to each disease and situation -- backed by the clincal expertise and authority of world recognized oncology researchers/practitioners. Key Features REVISED: competely updated coverage of the quickly evolving world of cancer therapeutics NEW: chapters include "Expert Commentary Sidebars" that provide clinical insights from leading subspecialists in radiation therapy, surgical oncology, pathology, and laboratory medicine NEW: brand new chapters on myelodysplasia, myeloproliferative diseases, and appendiceal cancer NEW: a brand new chapter on the important and underpublished topic of psycho-social issues in oncology Consistently formatted for a unified patient management strategy Packed with time-saving features, including The MD Anderson Work-Up Box and The MD Anderson Preferred Treatment Box

Drugs in Cancer Care

Drugs in Cancer Care Book
Author : Rachel Midgley,Mark R. Middleton,Andrew Dickman,David Kerr
Publisher : OUP Oxford
Release : 2013-06-06
ISBN : 0191641715
Language : En, Es, Fr & De

GET BOOK

Book Description :

The treatment of cancer has undergone dramatic evolutions in the past two decades and the provision of holistic care by a multidisciplinary team of specialists is emerging as the cornerstone of recent improvements in outcome. Accompanying this multidisciplinary approach is the increasing complexity of therapeutic agents and modalities utilized. Drugs in Cancer Care is a succinct, practical and user-friendly guide to commonly used drugs and non-surgical therapeutic modalities in oncology. This detailed yet concise handbook contains over 90 monographs of cancer care providing the information needed to deliver chemotherapy with safety and precision, including information on mechanism of action, clinical pharmacology, side effect profile, tumour indications, combination treatment and how to respond to the hepato-renal impairment seen in many patients with advanced cancer. In an easy to use A-Z format this handbook will appeal to a variety of healthcare professional involved in the provision of cancer care and medicine information and will become an essential and well-thumbed item in every oncologist's toolkit.